Ilias Ioannis, Torpy David J, Pacak Karel, Mullen Nancy, Wesley Robert A, Nieman Lynnette K
Pediatric and Reproductive Endocrinology Branch, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1109, USA.
J Clin Endocrinol Metab. 2005 Aug;90(8):4955-62. doi: 10.1210/jc.2004-2527. Epub 2005 May 24.
Ectopic ACTH secretion (EAS) is difficult to diagnose and treat. We present our experience with EAS from 1983 to 2004.
The study was performed at a tertiary care clinical research center.
Ninety patients, aged 8-72 yr, including 48 females were included in the study.
Tests included 8 mg dexamethasone suppression, CRH stimulation, inferior petrosal sinus sampling (IPSS), computed tomography, octreotide scan, magnetic resonance imaging, and/or venous sampling. Therapies, pathological examinations, and survival were noted.
Eighty-six to 94% of patients did not respond to CRH or dexamethasone suppression, whereas 66 of 67 had negative IPSS. To control hypercortisolism, 62 patients received medical treatment, and 33 had bilateral adrenalectomy. Imaging localized tumors in 67 of 90 patients. Surgery confirmed an ACTH-secreting tumor in 59 of 66 patients and cured 65%. Nonthymic carcinoids took longest to localize. Deaths included three of 35 with pulmonary carcinoid, two of five with thymic carcinoid, four of six with gastrinoma, two of 13 with neuroendocrine tumor, two of two with medullary thyroid cancer, one of five with pheochromocytoma, three of three with small-cell lung cancer, and two of 17 with occult tumor. Patients with other carcinoids and ethesioneuroblastoma are alive.
IPSS best identifies EAS. Initial failed localization is common and suggests pulmonary carcinoid. Although only 47% achieved cure, survival is good except in patients with small-cell lung cancer, medullary thyroid cancer, and gastrinoma.
异位促肾上腺皮质激素(ACTH)分泌(EAS)难以诊断和治疗。我们介绍了1983年至2004年期间我们治疗EAS的经验。
该研究在一家三级医疗临床研究中心进行。
90例患者,年龄8至72岁,其中包括48名女性,被纳入该研究。
检查包括8毫克地塞米松抑制试验、促肾上腺皮质激素释放激素(CRH)刺激试验、岩下窦采血(IPSS)、计算机断层扫描、奥曲肽扫描、磁共振成像和/或静脉采血。记录治疗方法、病理检查结果和生存率。
86%至94%的患者对CRH或地塞米松抑制试验无反应,而67例患者中有66例IPSS结果为阴性。为控制高皮质醇血症,62例患者接受了药物治疗,33例患者接受了双侧肾上腺切除术。影像学检查在90例患者中的67例发现了肿瘤。手术证实66例患者中有59例存在分泌ACTH的肿瘤,治愈率为65%。非胸腺类癌定位所需时间最长。死亡病例包括35例肺类癌患者中的3例、5例胸腺类癌患者中的2例、6例胃泌素瘤患者中的4例、13例神经内分泌肿瘤患者中的2例、2例甲状腺髓样癌患者中的2例、5例嗜铬细胞瘤患者中的1例、3例小细胞肺癌患者中的3例以及17例隐匿性肿瘤患者中的2例。其他类癌和嗅神经母细胞瘤患者存活。
IPSS是诊断EAS的最佳方法。最初未能定位肿瘤很常见,提示可能为肺类癌。虽然只有47%的患者实现了治愈,但除小细胞肺癌、甲状腺髓样癌和胃泌素瘤患者外,患者的生存率良好。